35 in stock
Product name: MK-2866
Molecular Formula: C19H14F3N3O3
Description: MK-2866 is an oral SARM with rapid repair capabilities in subjects. It binds to the androgen receptors in the muscles to cut down recovery times and ramp up rapid healing in muscle tissue. MK-2866 has gained notoriety in mainstream competitive sports and is currently under development for commercial use as an anti-muscle wasting agent and rapid repair compound.
|Bottle:||Premium Ceramic Dropper|
|1 x Bottle MK-2866 (30ml)|
|Classification||Premium Research Chemicals|
Elite Scientific Analysis:
MK-2866 (Enobosarm, GTx-024, Ostarine) is an oral selective androgen receptor modulator (SARM) with rapid repair capabilities in subjects. It binds to the androgen receptors in the muscles to cut down recovery times and ramp up rapid healing in muscle tissue.
MK2866 is a non-steroidal agent with anabolic activity and is designed to work like testosterone, thus promoting and/or maintaining libido, fertility, prostate growth, and muscle growth and strength. Mimicking testosterone’s action, this agent may increase lean body mass thereby ameliorating muscle wasting in the hypermetabolic state of cancer induced cachexia.
Because it only sparingly affects reproductive tissue it does not have the negative side effects that can be related to testosterone.
This compound was initially developed for use as a treatment in muscle wasting diseases but has gained notoriety in mainstream competitive sports and bodybuilding due to its effectiveness at increasing muscle mass and perceived positive impact on injury rehabilitation progression.
In a 22015 study on MK2866 and the expression of the muscle-specific androgen-responsive genes S-adenosylmethionine decarboxylase and myostatin were decreased by orchidectomy and restored by MK-2866 and DHT in control mice.
The mechanism of action of MK-2866 on skeletal muscle is partly direct via muscle androgen receptor activation and part of the anabolic effect seems to be indirect via non-muscle androgen receptor pathways. Muscle fibroblasts may play a role in these indirect pathways.
The MK2866 compound is currently under development for commercial use as an anti-muscle wasting agent and rapid repair compound and is in Phase III clinical trials for the prevention and treatment of muscle wasting in patients with cancer.
It has proven to be quite beneficial in healing and displays potential for preventing injuries in tendons, bone, and ligaments.
It has consistently demonstrated increases in lean body mass and better physical function across several populations along with a lower hazard ratio for survival in cancer patients.
On the whole this compound promises to be extremely effective at building muscle and aiding in healing without significant side effects.
- Dalton J. T., Taylor R. P., Mohler M. L., Steiner M. S., Selective androgen receptor modulators for the prevention and treatment of muscle wasting associated with cancer. Current opinion in supportive and palliative care, 2013, 7(4), 345-351.
- Molfino A., Amabile M. I., Rossi Fanelli F., Muscaritoli M., Novel therapeutic options for cachexia and sarcopenia, Expert opinion on biological therapy, 2016, 16(10), 1239-1244.
- Crawford J., Prado C. M., Johnston M. A., Gralla R. J., Taylor R. P., Hancock M. L., Dalton J. T., Study design and rationale for the phase 3 clinical development program of enobosarm, a selective androgen receptor modulator, for the prevention and treatment of muscle wasting in cancer patients (POWER trials), Current oncology reports, 2016, 18(6), 37.
- Dubois V., Simitsidellis I., Laurent M. R., Jardi F., Saunders P. T., Vanderschueren D., Claessens F., Enobosarm (GTx-024) modulates adult skeletal muscle mass independently of the androgen receptor in the satellite cell lineage, Endocrinology, 2015, 156(12), 4522-4533.